Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Yoshie Morimoto"'
Autor:
Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, Naoko Okura, Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Kenji Kita, Seiji Yano, Koichi Takayama
Publikováno v:
Cancer Medicine, Vol 11, Iss 4, Pp 944-955 (2022)
Abstract EGFR‐T790M mutation is a major mechanism underlying acquired resistance to first‐ and second‐generation EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in lung cancer with mutated EGFR. However, differences in the biological characterist
Externí odkaz:
https://doaj.org/article/59a3f3ff4edb4685a7f4cb5af5d2b0ba
Autor:
Masaki Ishida, Kenji Morimoto, Tadaaki Yamada, Shinsuke Shiotsu, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Takeda, Koichi Takayama
Publikováno v:
Thoracic Cancer, Vol 13, Iss 2, Pp 173-181 (2022)
Abstract Background Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non‐small‐cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the sele
Externí odkaz:
https://doaj.org/article/957f69dde99b46e1a7ef430e0b3218f5
Autor:
Keiko Tanimura, Tadaaki Yamada, Koutaroh Okada, Kunihiro Nakai, Mano Horinaka, Yuki Katayama, Kenji Morimoto, Yuri Ogura, Takayuki Takeda, Shinsuke Shiotsu, Kosuke Ichikawa, Satoshi Watanabe, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hirokazu Taniguchi, Kazue Yoneda, Satoaki Matoba, Toshiyuki Sakai, Hisanori Uehara, Seiji Yano, Tetsuro Kusaba, Ryohei Katayama, Koichi Takayama
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-12 (2022)
Abstract Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have shown dramatic efficacy in patients with ALK-rearranged lung cancer; however, complete response in these patients is rare. Here, we investigated the molecular mechanisms u
Externí odkaz:
https://doaj.org/article/22d87946d66b4cc0afe194c4ecc063ef
Autor:
Makoto Hibino, MD, Osamu Hiranuma, MD, Yoshizumi Takemura, MD, PhD, Yuki Katayama, MD, Yusuke Chihara, MD, PhD, Taishi Harada, MD, Kohei Fujita, MD, PhD, Toshiyuki Kita, MD, PhD, Nobuyo Tamiya, MD, PhD, Takeshi Tsuda, MD, Shinsuke Shiotsu, MD, Yukihiro Tamura, MD, PhD, Takashi Aoyama, MD, Yoichi Nakamura, MD, PhD, Masaaki Terashima, MD, PhD, Yoshie Morimoto, MD, PhD, Kazuhiro Nagata, MD, PhD, Kenichi Yoshimura, PhD, Junji Uchino, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100424- (2022)
Introduction: First-line treatment of EGFR-mutated NSCLC with erlotinib plus antiangiogenic inhibitor exhibits promising results. However, the efficacy of this combination has not been fully investigated. Therefore, we evaluated the efficacy and safe
Externí odkaz:
https://doaj.org/article/a09bdb92643c488189791c1af982e3fb
Autor:
Kenji Morimoto, MD, PhD, Ryo Sawada, MD, Tadaaki Yamada, MD, PhD, Koichi Azuma, MD, PhD, Kentaro Ito, MD, Yasuhiro Goto, MD, PhD, Hideharu Kimura, MD, PhD, Taishi Harada, MD, Shinsuke Shiotsu, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Takayuki Takeda, MD, PhD, Osamu Hiranuma, MD, Isao Hasegawa, MD, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100388- (2022)
Introduction: The use of immune checkpoint inhibitors (ICIs) with chemotherapy has increased the survival of patients with advanced NSCLC. Nevertheless, the efficacy of ICI treatment for NSCLC with EGFR mutations is limited. Previous studies have not
Externí odkaz:
https://doaj.org/article/1e1fc663904a4f5abcb4031e0440a538
Autor:
Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Takayuki Nakano, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100353- (2022)
Introduction: To date, the efficacy and safety of programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy for patients with extensive-stage SCLC (ES-SCLC), with real-world evidence, stratified on the basis of age and performa
Externí odkaz:
https://doaj.org/article/c7edde061feb4e788e7779457729f41b
Autor:
Hiroyuki Fujii, Masahiro Iwasaku, Haruka Kuno, Naohiro Nitta, Hiroki Ueda, Tatsuya Yoshikawa, Saeko Usui, Tatsuya Hirota, Natsuko Hayashi, Akihiro Yoshimura, Yoshie Morimoto, Shinsaku Tokuda, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 6, Iss , Pp 100164- (2022)
We describe a rare case of concurrent adverse events of hemoptysis and pulmonary embolism in a patient with unresectable thymic carcinoma treated with lenvatinib. A 73-year-old man undergoing treatment with lenvatinib 20 mg/day presented to our emerg
Externí odkaz:
https://doaj.org/article/be51642ae4a7498b8f730b9e7217ba4f
Autor:
Keiko Tanimura, Tadaaki Yamada, Ayaka Omura, Shinsuke Shiotsu, Nobutaka Kataoka, Takayuki Takeda, Ryusuke Taniguchi, Takahiro Yamada, Mayumi Takeuchi, Yusuke Chihara, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundIn recent years, immune checkpoint inhibitors (ICIs) in combination with chemotherapy have increased survival in patients with advanced non-small cell lung cancer (NSCLC). Vascular endothelial growth factor (VEGF), which plays a key role in
Externí odkaz:
https://doaj.org/article/d9349b43452e4bbb8a2b3c759b914686
Autor:
Kenji Morimoto, Tadaaki Yamada, Chieko Takumi, Yuri Ogura, Takayuki Takeda, Keisuke Onoi, Yusuke Chihara, Ryusuke Taniguchi, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associa
Externí odkaz:
https://doaj.org/article/b6d5ff2d94894c90b0b39dd30a854495
Autor:
Kenji Morimoto, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Goto, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, Chieko Takumi, Masafumi Takeshita, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of cancer cachexia on chemoimmunotherapy is unclear. We investigated the impact of cancer cachexia on the thera
Externí odkaz:
https://doaj.org/article/00eade7d965441ed9248ced0cdf5d785